Optometric glaucoma referrals - measures of effectiveness and implications for screening strategy

2000 ◽  
Vol 20 (6) ◽  
pp. 452-463
Author(s):  
Jim Gilchrist
1998 ◽  
Vol 1643 (1) ◽  
pp. 152-160 ◽  
Author(s):  
F. R. Hanscom ◽  
M. W. Goelzer

A software tool was developed to determine what is accomplished as the result of truck weight enforcement efforts. Traditionally applied measures (e.g., numbers of trucks weighed and citations issued) have simply provided indications of enforcement effort. These previously applied measures failed to provide results in terms of real enforcement objectives, such as deterring overweight trucks and minimizing pavement wear and tear. Consequently the need exists to develop and validate truck weight enforcement measures of effectiveness (MOE). MOEs were developed via a series of analytical procedures. They were subsequently validated in a comprehensive four-state field evaluation. Matched (weigh-in-motion) (WIM) data sets, collected under controlled baseline and enforcement conditions, were analyzed to determine the sensitivity of candidate MOEs to actual enforcement activity. Data collection conditions were controlled in order to avoid contamination from hour-of-day, day-of-week, and seasonal effects. The following MOEs, were validated on the basis of their demonstrated sensitivity to truck weight enforcement objectives and the presence of enforcement activity: (1) severity of overweight violations, (2) proportion of overweight trucks, (3) average equivalent single-axle load (ESAL), (4) excess ESALs, and (5) bridge formula violations. These measures are sensitive to legal load-limit compliance objectives of truck weight enforcement procedures as well as the potential for overweight trucks to produce pavement deterioration. The software User Guide that statistically compares calculated MOEs between observed enforcement conditions is described in this paper. The User Guide also allows users to conduct an automated pavement design life analysis estimating, the theoretical pavement-life effect resulting from the observed enforcement activity.


Author(s):  
Vikram Parthasarathy ◽  
Achuthan Raghava Menon ◽  
Basavaraj Devaranavadagi

Background: The anticancer properties of natural products calactin, calotropin and calotoxin are well established. However the mechanisms of their action are unclear and the molecular targets pertinent to them are not detailed. In this study, potential anti-cancer targets of these compounds have been identified using reverse screening approaches that may provide valuable insights into anti cancer drug development. Objective: To identify the potential anticancer targets of calactin, calotropin and calotoxin using reverse screening strategy. Methods: The ligands were screened for potential targets based on their shape similarity and pharmacophore model matching. The overlapping targets obtained from both methods were verified using reverse docking approach and validated by docking analysis. MM/PBSA calculation was performed to predict binding affinities between ligand and confirmed targets. Results: Interleukin-2 inducible T cell kinase [ITK] was confirmed as a potential target of calactin (Ki= -10.3 kcal/mol), calotropin (Ki= -8.7 kcal/mol) and calotoxin (Ki= -10.2 kcal/mol). The ligands interacted with hinge region residues such as Met438 and Asp500 which occupy the highly conserved ATP binding site. Binding energies of calactin (∆Ebind = -29.18 kJ/mol), calotropin (-28.57 kJ/mol) and calotoxin (-21.21 kJ/mol) with ITK were higher than (more negative) positive control sunitinib (-15.03 kJ/mol) and standard staurosporine (-21.09 kJ/mol). Besides this, Interstitial collagenase [MMP1] was confirmed as potential target of calotoxin (Ki= -8.2 kcal/mol).However the binding energy (∆Ebind = -11.89 kJ/mol) was lower compared to positive control batimastat (-21.07 kJ/mol). Conclusion: The results of this study confirmed ITK as a potential target for calactin, calotropin and calotoxin. These compounds can therefore be used as lead molecules for the development of novel ITK inhibitors, which may have immense therapeutic applications as immune-suppressants and as anticancer drugs.


Sign in / Sign up

Export Citation Format

Share Document